[Pharmacokinetic and clinical studies on cefodizime in the field of obstetrics and gynecology].
Pharmacokinetic and clinical studies on cefodizime (THR-221, CDZM) were carried out and the following results were obtained. Concentrations of CDZM in serum and uterine tissues were determined from 38 to 282 minutes after drip infusion of 1 g CDZM. CDZM reached peak level of 25.0 micrograms/g or higher in each tissue during a period of 38 to 83 minutes. Concentrations of CDZM in the dead space exudate after drip infusion of 2 g CDZM were also studied. At 240 minutes after injection, CDZM concentration in exudate reached a peak of 46.88 micrograms/ml. These levels far exceeded MICs of CDZM against major pathogens most often isolated in the field of obstetrics and gynecology. CDZM was administered to 7 patients with their diseases diagnosed as pelvic peritonitis (4 cases) or acute adnexitis (3 cases) at a dose of 2-4 g per day for 6-14. days. Clinical response was good in all cases. Transient elevation of liver function was noticed in 2 cases. No other adverse reactions were noted during the study.
Lin
B L
BL
Department of Obstetrics and Gynecology, Kawasaki Municipal Hospital.
Iwata
Y
Y
D000328:Adult; D001419:Bacteria / Q000187:drug effects; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000378:metabolism; D010538:Peritonitis / Q000188:drug therapy* / Q000378:metabolism; D014599:Uterus / Q000378:metabolism*
D002439:Cefotaxime; C033356:cefodizime